Last updated on June 2016

A randomised, double-blind, placebo-controlled, proof-of concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis.


Brief description of study

A randomised, double-blind, placebo-controlled, proof-of concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis.

Detailed Study Description

Psoriatic arthritis is a chronic inflammatory disease which can affect any joint in your body. Psoriatic arthritis usually develops in people who have psoriasis, a disease in which scaly red and white patches develop on the skin. Both psoriasis and psoriatic arthritis are caused by an overactive immune system where healthy body tissue is attacked by mistake. This study will look at a new investigational drug, BI 655066, and provide proof-of-concept and dose-ranging data of BI 655066 in patients with active psoriatic arthritis.

Clinical Study Identifier: TX144054

Contact Investigators or Research Sites near you

Start Over

Michelle Orzechowski

University of South Florida - Morsani Center for Advanced Healthcare
Tampa, FL USA
  Connect »